TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17394010

Group type: EXPERIMENTAL
Intervention: WP1 (three sets of five jumps with extra load)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WP2 (two sets of four reps at 80% of 1RM(PS) and two sets of two reps at 85% of 1RM(PS))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WP3 (two sets of four reps at 80% of 1RM(PS), two sets of two reps at 90% of 1RM(PS), and two sets of one rep at 95% of 1RM(PS))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WP4 (three sets of five DJs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WP5 (specified warm-up for a volleyball match)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WP6 (three sets of five reps at 30% 1RM(PS))
Number of subjects: 12

Group type: COMPARATOR
Intervention: No active warm-up (control condition)
Number of subjects: 12
Study: 15522911

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 28 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (non-obese subjects)
Number of subjects: 29
Study: 11783048

Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 87
Study: 9848065

Group type: EXPERIMENTAL
Intervention: Topical steroid therapy (short-time)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Topical steroid therapy (long-time)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy (bolus group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Systemic steroid therapy (tapering group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Laser tyndallometry
Number of subjects: 99
Study: 7584303

Group type: EXPERIMENTAL
Intervention: Passive exposure to three activities during the reactivation session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not reminded or did not engage in the activities)
Number of subjects: 0
Study: 2576886

Group type: EXPERIMENTAL
Intervention: Somatostatin (SMS) administered epidurally
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Somatostatin (SMS) administered epidurally in group A (procto-anal)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Somatostatin (SMS) administered epidurally in group B (inguino-crural)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 1001205

Group type: EXPERIMENTAL
Intervention: Clofibate and phenformin
Number of subjects: 15
Study: 31120614

Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine (0.2% at 4‐6 ml/h)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 96
Study: 28012403

Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy based on analog insulin (detemir/aspart)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Basal-bolus therapy based on human insulin (NPH/regular)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Analog insulin treatment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Human insulin treatment
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both treatments (analog and human insulin)
Number of subjects: 114
Study: 26046455

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with fentanyl 5 μg/mL
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with fentanyl 5 μg/mL and epinephrine 5 μg/mL
Number of subjects: 402
Study: 23330900

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements by students
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physical examination by physicians
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Variance in student measurements
Number of subjects: 10

Group type: COMPARATOR
Intervention: Variance in physician measurements
Number of subjects: 10
Study: 21789429

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg/day of soy protein
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg/day of soy protein plus fibers
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0.8 g/kg/day of animal protein
Number of subjects: 27
Study: 19247779

Group type: EXPERIMENTAL
Intervention: Parental presence during anesthesia induction
Number of subjects: 14

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Parental presence plus midazolam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Parental presence plus video game
Number of subjects: 14

Group type: COMPARATOR
Intervention: No parental presence
Number of subjects: 14
Study: 17302782

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (target hematocrit level of 28%)
Number of subjects: 40
Study: 15220950

Group type: EXPERIMENTAL
Intervention: Regular meal frequency (6 occasions per day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Irregular meal frequency (3-9 meals/day)
Number of subjects: 9
Study: 11437696

Group type: EXPERIMENTAL
Intervention: Newer 5-ASA formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard dosages of mesalazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-ASA-containing preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminosalicylates
Number of subjects: 0
Study: 9678070

Group type: EXPERIMENTAL
Intervention: 0.28 mg ethinylestradiol monthly + 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.32 mg ethinylestradiol monthly + 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both regimens (0.28 mg and 0.32 mg ethinylestradiol)
Number of subjects: 18
Study: 8026301

Group type: EXPERIMENTAL
Intervention: Ethanol 1.00 g/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol 0.50 g/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol 0.75 g/kg
Number of subjects: 0
Study: 2530317

Group type: COMPARATOR
Intervention: Intravenous floxuridine (IV FUDR)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Hepatic intraarterial floxuridine (IA FUDR)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Comparison of IV FUDR and IA FUDR
Number of subjects: 143
Study: 1027635

Group type: EXPERIMENTAL
Intervention: Fortagesic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paramol 118
Number of subjects: 0
Study: 31475798

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 19220

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 19220
Study: 29049935

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OT) 36 IU daily for 4-6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OT)
Number of subjects: 0
Study: 27461394

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion (SPG) stimulation
Number of subjects: 33
Study: 24828035

Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg b.i.d.
Number of subjects: 8442

Group type: COMPARATOR
Intervention: Enalapril 10 mg b.i.d.
Number of subjects: 8442
Study: 22825654

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) administered orally prior to FDG-PET in 65 patients
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (65 patients without PPI)
Number of subjects: 130
Study: 19936917

Group type: EXPERIMENTAL
Intervention: UFT (oral tegafur-uracil) for 2 years
Number of subjects: 1057

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) for six courses
Number of subjects: 1057
Study: 17706404

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Three-dimensional radiotherapy (control arm)
Number of subjects: 5
Study: 15956984

Group type: EXPERIMENTAL
Intervention: Amoxapine (up to 250 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Risperidone (up to 5 mg/day)
Number of subjects: 48
Study: 12385688

Group type: EXPERIMENTAL
Intervention: pivmecillinam 200 mg tid for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pivmecillinam 200 mg bid for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pivmecillinam 400 mg bid for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: norfloxacin 400 mg bid for 3 days
Number of subjects: 0
Study: 10447316

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for at least 24 weeks
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Negative qualitative HCV RNA test after 12 weeks of interferon treatment
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Prolonged treatment with interferon-alpha (> 6 months)
Number of subjects: 172
Study: 7839429

Group type: EXPERIMENTAL
Intervention: Low dose arginine vasopressin (AVP) infusion, n = 11
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (Control), n = 13
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low dose arginine vasopressin (AVP) infusion
Number of subjects: 24
Study: 2201722

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg with ethanol (0.2‐0.4 g/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg with ethanol (0.2‐0.4 g/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ethanol alone (0.2‐0.4 g/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg and Nitrazepam 5 mg with ethanol
Number of subjects: 9
Study: 1256966

Group type: EXPERIMENTAL
Intervention: Objects group (high cues)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Slides group (low cues)
Number of subjects: 40
Study: 30445461

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aerobic Exercise (AER) and Resistance Exercise (RES) combined
Number of subjects: 24
Study: 28823623

Group type: EXPERIMENTAL
Intervention: EMLA®
Number of subjects: 150

Group type: COMPARATOR
Intervention: J-Tip Needleless Injection System®
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 150
Study: 25929699

Group type: EXPERIMENTAL
Intervention: CRT-D in women with ischemic heart disease
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: CRT-D in women with LBBB
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: CRT-D in men with LBBB
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: ICD in ischemic women
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: ICD in nonischemic women
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Appropriate shock therapy in women
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Appropriate shock therapy in men
Number of subjects: 1790
Study: 23761424

Group type: COMPARATOR
Intervention: Maximal voluntary contraction (MVC) in contralesional limb
Number of subjects: 7

Group type: COMPARATOR
Intervention: Maximal voluntary contraction (MVC) in ipsilesional limb
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Activation deficits
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EMG amplitude deficits
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Antagonist coactivation percentage
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Muscle volume
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 50 Hz torque
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Specific torque (50Hz torque/muscle volume)
Number of subjects: 7
Study: 22029549

Group type: EXPERIMENTAL
Intervention: Atomoxetine 25-100 mg (mean final dose = 89.9 mg)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: On-treatment drinking levels
Number of subjects: 147
Study: 18284391

Group type: EXPERIMENTAL
Intervention: Resin salve
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sodium carboxymethylcellulose hydrocolloid polymer treatment
Number of subjects: 37
Study: 17175743

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 12464717

Group type: EXPERIMENTAL
Intervention: Madopar DR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Madopar HBS
Number of subjects: 20
Study: 11115954

Group type: EXPERIMENTAL
Intervention: RTV 200 mg once daily (group A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RTV 400 mg once daily (group B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg (day 1), 400 mg (day 15), 800 mg (day 18), 1200 mg (day 21)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indinavir 1200 mg/400 mg RTV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg/400 mg RTV or 1200 mg/200 mg RTV
Number of subjects: 12
Study: 9339786

Group type: EXPERIMENTAL
Intervention: Computerized dynamic posturography in suspected malingerers
Number of subjects: 541

Group type: COMPARATOR
Intervention: Computerized dynamic posturography in normal subjects
Number of subjects: 541

Group type: COMPARATOR
Intervention: Computerized dynamic posturography in patients with balance disorders
Number of subjects: 541
Study: 8456478

Group type: EXPERIMENTAL
Intervention: Hyperosmolar citrate (HOC) reflush
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phosphate‐buffered sucrose (PBS140) reflush
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Reflush
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reflushing (both HOC and PBS140)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (HOC, PBS140, No Reflush)
Number of subjects: 30
Study: 2420106

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) continuous infusion (400 micrograms bolus followed by 200 micrograms/hour for 6 hours)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31916578

Group type: EXPERIMENTAL
Intervention: LHW-led educational sessions (smoking cessation intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy living intervention)
Number of subjects: 0
Study: 29530838

Group type: EXPERIMENTAL
Intervention: Provider profiles with educational tweets
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Female provider profiles with mixed content
Number of subjects: 6

Group type: COMPARATOR
Intervention: Male provider profiles with mixed content
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Female provider profiles with only personal content
Number of subjects: 6

Group type: COMPARATOR
Intervention: Male provider profiles with only personal content
Number of subjects: 6
Study: 27630127

Group type: EXPERIMENTAL
Intervention: Daratumumab, bortezomib, and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib plus dexamethasone
Number of subjects: 0
Study: 25754845

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 382

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no MBP)
Number of subjects: 382
Study: 23835819

Group type: EXPERIMENTAL
Intervention: Telephone outreach by MMCO staff
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Telephone outreach (as-treated comparison)
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Usual care (as-treated comparison)
Number of subjects: 2240
Study: 20889343

Group type: EXPERIMENTAL
Intervention: Certainty of direction of perturbation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased supra-postural task constraint (equilibrating a cylinder on the tray)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of certainty and high supra-postural task constraint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbation with certainty and increased constraint
Number of subjects: 0
Study: 18503589

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study: 16830139

Group type: EXPERIMENTAL
Intervention: Flicker stress using a full-field stimulator with white LEDs at a frequency of 37 Hz
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Flicker provocation test
Number of subjects: 154
Study: 12762269

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10861335

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Creatine supplementation and Placebo
Number of subjects: 19
Study: 8785030

Group type: EXPERIMENTAL
Intervention: Local intra-arterial injection of cisplatin at a dose of 100 mg concomitant with hemodialysis (HD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local intra-arterial injection of cisplatin at doses of 200 or 250 mg concomitant with hemodialysis (HD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local intra-arterial injection of cisplatin (dose not specified) without concomitant hemodialysis (HD)
Number of subjects: 0
Study: 8256883

Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3890473

Group type: EXPERIMENTAL
Intervention: Cognitive‐affective stress management training (SMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30936689

Group type: EXPERIMENTAL
Intervention: Home-based disease management (DM)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Usual management (UM)
Number of subjects: 319
Study: 29524467

Group type: EXPERIMENTAL
Intervention: Self-relevant contexts (positive opinions about participants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive, self-referential contexts with direct gaze
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral faces with gaze manipulation (direct and averted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral faces with contextual sentences (positive or negative)
Number of subjects: 0
Study: 27600381

Group type: EXPERIMENTAL
Intervention: Post-discharge intervention provided by a social worker
Number of subjects: 151

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Post-discharge intervention with interdisciplinary meeting of significant network members
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Post-discharge intervention with involuntary index admission
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Post-discharge intervention with high educational degree
Number of subjects: 151
Study: 25276418

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 268

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 268
Study: 22577884

Group type: EXPERIMENTAL
Intervention: Diabetics software
Number of subjects: 48

Group type: COMPARATOR
Intervention: Caloric tables and mental calculations (Control)
Number of subjects: 48
Study: 20924975

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (200 mg daily for 6 months)
Number of subjects: 42
Study: 18602960

Group type: EXPERIMENTAL
Intervention: PTL-003 (live, attenuated CS1/CS3 ETEC strain)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PTL-003
Number of subjects: 33
Study: 16423097

Group type: EXPERIMENTAL
Intervention: Intervention group (academic detailing and direct mailings to patients)
Number of subjects: 9652
Study: 11755589

Group type: EXPERIMENTAL
Intervention: Load cycling (90N for 5000 cycles) with Clearfil SE Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Load cycling (90N for 5000 cycles) with Unifil Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Load cycling (90N for 5000 cycles) with Prompt L-Pop
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Load cycling (90N for 5000 cycles) with Single Bond
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-load cycling (control group) with Clearfil SE Bond
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-load cycling (control group) with Unifil Bond
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-load cycling (control group) with Prompt L-Pop
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-load cycling (control group) with Single Bond
Number of subjects: 0
Study: 10691065

Group type: COMPARATOR
Intervention: Information brochure
Number of subjects: 10048

Group type: COMPARATOR
Intervention: $2 cash incentive
Number of subjects: 10048

Group type: COMPARATOR
Intervention: $5 cash incentive
Number of subjects: 10048

Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 10048
Study: 9062854

Group type: EXPERIMENTAL
Intervention: SFSP2
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SFSP1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: G
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SF1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SF2
Number of subjects: 21

Group type: COMPARATOR
Intervention: C (NaF toothpaste)
Number of subjects: 21

Group type: COMPARATOR
Intervention: S (saline)
Number of subjects: 21
Study: 3015041

Group type: EXPERIMENTAL
Intervention: COM-ANV therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ANV-COM therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Limited Disease (LD)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Extensive Disease (ED)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ANV therapy
Number of subjects: 39
Study: 29532784

Group type: EXPERIMENTAL
Intervention: Family Therapy (FT)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 832
Study: 27347788

Group type: EXPERIMENTAL
Intervention: TRANSITECH (2 tablets daily for 10 days)
Number of subjects: 100
Study: 23317087

Group type: EXPERIMENTAL
Intervention: Shared attention with similar others
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing the same object with dissimilar others
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing a different object with similar others
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing a different object with different others
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing the object alone with no others present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared attention condition
Number of subjects: 0
Study: 22244707

Group type: EXPERIMENTAL
Intervention: Baclofen 10mg t.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24